Advantages of eslicarbazepine in the treatment of patients with fоcalepilepsy
DOI:
https://doi.org/10.67667/NEU.v25i1.154Keywords:
Eslicarbazepine acetate, Partial-onset epilepsy, Efficacy, Side effectsAbstract
Epilepsies are among the most common chronic disorders of the brain and affect approximately 70 million people worldwide. The management of epilepsy is mainly symptomatic, aimed at reducing the risk of seizure recurrence. Despite the availability of many therapeutic options, more than 50% of patients do not achieve seizure freedom with initial monotherapy and despite combination therapy seizures remain uncontrolled in approximately one third of patients.
The most frequent type of seizure is the partial-onset (focal) seizure.
Eslicarbazepine acetate is a new antiepileptic drug, third-generation relative of carbamazepine and oxcarbazepine that is less prone to drug interactions and better tolerated, taken once per day. Eslicarbazepine acetate was first approved as adjunctive therapy against partial-onset seizures, followed by a monotherapy indication after successful completion of monotherapy conversion trials. Clinical studies using eslicarbazepine acetate as adjunctive treatment or monotherapy have demonstrated its efficacy in patients with refractory or newly diagnosed focal seizures. The drug is generally well tolerated, and the most common side effects include dizziness, headache, and diplopia. Eslicarbazepine acetate has many advantages over older antiepileptic drugs, and it should be necessarily considered when treating patients with partial-onset epilepsy.
References
Almeida, L., Falcao, A., Maia, J., Mazur, D., Gellert, M., SoaresdaSilva, P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol, 2005, 45, 9, 1062-1066.
Almeida, L., Minciu, I., Nunes, T., Butoianu, N., Falcao, A., Magureanu, S., et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol, 2008, 48, 8, 966-977.
American Academy of Neurology 68th Annual Meeting; 2016. Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures.
Banach, M., Borowicz, K., Czuczwar, S. Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy. Expert Opin Drug Metab Toxicol, 2015, 11, 4, 639-648.
Ben-Menachem, E., Gabbai, A., Hufnagel, A., Maia, J., Almeida, L., Soares-da-Silva, P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res, 2010, 89, 2-3, 278-285.
Bialer, M., Soares-da-Silva, P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia, 2012, 53, 6, 935-946.
Correia, F., Freitas, J., Magalhaes, R., Lopes, J., Ramalheira, J., Lopes-Lima, J., et al. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study. Epilepsy Res, 2014, 108, 8, 1399-1405.
Elger, C., Bialer, M., Cramer, J., Maia, J., Almeida, L., SoaresdaSilva, P. Eslicarbazepine acetate: a double-blind, add-on, placebocontrolled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007, 48, 3, 497-504.
Elger, C., Bialer, M., Falcao, A., Vaz-da-Silva, M., Nunes, T., Almeida, L., et al. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia. 2013, 54, 8, 1453-1461.
Elger, C., Halasz, P., Maia, J., Almeida, L., Soares-da-Silva, P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia, 2009, 50, 3, 454-463.
Falcao, A., Pinto, R., Nunes, T., Soares-da-Silva, P. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res, 2013, 106, 1-2, 244-249.
Falcao, A., Vaz-da-Silva, M., Gama, H., Nunes, T., Almeida, L., Soares-da-Silva, P. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res, 2013, 105(3): 368-376.
Gil-Nagel, A., Lopes-Lima, J., Almeida, L., Maia, J., Soares-da-Silva, P. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partialonset seizures. Acta Neurol Scand, 2009, 120, 5, 281-287.
Hainzl, D., Parada, A., Soares-da-Silva, P. Metabolism of two new antiepileptic drugs and their principal metabolites S(?)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res, 2001, 44, 2-3, 197-206.
Halasz, P., Cramer, J., Hodoba, D., Czlonkowska, A., Guekht, A., Maia, J., et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partialonset seizures in adults with epilepsy. Epilepsia, 2010, 51, 10, 1963-1969.
Hebeisen, S., Pires, N., Loureiro, A., Bonifacio, M., Palma, N., Whyment, A., et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology, 2015, 89: 122-135.
Hufnagel, A., Ben-Menachem, E., Gabbai, A., Falcao, A., Almeida, L., Soares-da-Silva, P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partialonset seizures in adults with epilepsy: results of a 1-year openlabel extension study. Epilepsy Res, 2013, 103, 2–3, 262-269.
Jacobson, M., Pazdera, L., Bhatia, P., Grinnell, T., Cheng, H., Blum, D. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurol, 2015, 15, 46.
Kwan, P., Arzimanoglou, A., Berg, A., Brodie, M., Allen Hauser, W., Mathern, G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51, 1069-1077.
Lattanzi, S., Trinka, E., Zaccara, G., Striano, P., Russo, E., Del Giovane, C., Silvestrini, M., Brigo, F. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Metaanalysis. Drugs, 2022, 82, 2, 199-218. doi: 10.1007/s40265-021-01661-4.
Maia, J., Almeida, L., Falcao, A., Soares, E., Mota, F., Potgieter, M., et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther, 2008, 46, 3, 119-130.
Peltola, J., Holtkamp, M., Rocamora, R., Ryvlin, P., Sieradzan, K., Villanueva, V. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate - Expert opinion. Epilepsy & Behavior, 2015, 50, 46-49.
Rocamora, R., Peltolab, J., Assenzac, G., McMurrayd, R., Vicente Villanuevae, V.: Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice; Seizure: European Journal of Epilepsy, 2020, 75, 121-128.
Rogawski, MA., Loscher, W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci, 2004, 5, 7, 553-564.
Singh, A., Trevick, S. The epidemiology of global epilepsy. Neurol Clin, 2016, 34, 4, 837-847.
Soares-da-Silva, P., Pires, N., Bonifacio, M., Loureiro, A., Palma, N., Wright, C. Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacol Res Perspect, 2015, 3, 2, e00124.
Sperling, M., Abou-Khalil, B., Harvey, J., Rogin, J., Biraben, A., Galimberti, C., et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia, 2015, 56, 2, 244-253.
Talevi, A. Antiseizure medication discovery: Recent and future paradigm shifts. Epilepsia, 2022, 7, 133-141. doi:10.1002/epi4.12581.
Trinka, E., Rocamora, R., Chaves, J., Moreira, J., Ikedo, F., Soares-da-Silva, P. BIA-2093-311/EXT Investigators Study Group. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study. Epilepsia, 2020, 61, 10, 2129-2141. doi: 10.1111/epi.16666.
Vaz-da-Silva, M., Almeida, L., Falcao, A., Soares, E., Maia, J., Nunes, T., et al. Effect of eslicarbazepine acetate on the steadystate pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, singleperiod study. Clin Ther, 2010, 32, 1, 179-192.
Vaz da Silva, M., Costa, R., Soares, E., Maia, J., Falcao, A., Almeida, L., et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol, 2009, 23, 4, 509-514.
Vilin, Y., Ruben, P. Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. Cell Biochem Biophys, 2001, 35, 2, 171-190.
Villanueva, V., Bermejo, P., Montoya, J., Toledo, M., Gomez-Ibanez, A., Garces, M., et al. EARLY-ESLI study: long-term experience with eslicarbazepine acetate after first monotherapy failure. Acta Neurol Scand, 2016, doi:10.1111/ane.12720.
Villanueva, V., Ojeda, J., Rocamora, R., Serrano-Castro, P., Parra, J., Rodríguez-Uranga, J., Bathal, H., Viteri, C. EPICON consensus: recommendations for proper management of switching to eslicarbazepine acetate in epilepsy. Neurologia, 2018, 33, 5, 290-300. doi: 10.1016/j.nrl.2016.04.014.
Zaccara, G., Giovannelli, F., Cincotta, M., Carelli, A., Verrotti, A. Clinical utility of eslicarbazepine: current evidence. Drug Des Devel Ther, 2015, 9, 781-789.
Zaccara, G., Perucc,a E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord, 2014, 16, 4, 409-431.
Zelano, J., Ben-Menachem, E. Eslicarbazepine acetate for the treatment of partial epilepsy. Expert Opin Pharmacother, 2016, 17(8): 1165-1169.
Downloads
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2024 Rumyana Kuzmanova, I. Vaneva
This work is licensed under a Creative Commons Attribution 4.0 International License.
